Skip to main content


Fig. 2 | BMC Medical Genomics

Fig. 2

From: Pitfalls of improperly procured adjacent non-neoplastic tissue for somatic mutation analysis using next-generation sequencing

Fig. 2

Overall flow chart of the two-stage analysis strategy. a, de-novo mutation calling and initial assessment of neoplasm contamination by using WES; b, targeted validation and ultra-deep sequencing to assess neoplasm contamination level in each adjacent non-neoplastic tissue. WES: whole exome sequencing; TAS: targeted amplicon sequencing; SNV: single nucleotide variant; VAF: variant allele fraction

Back to article page